SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc., (OTCBB:AEMD) announced today it will initiate research studies to test the in vitro effectiveness of the Aethlon Hemopurifier® to capture H5N1 Avian Influenza. Testing of the Hemopurifier® will be conducted through collaborations with researchers at Commonwealth Biotechnologies and Battelle Biomedical Research Center. Both organizations are approved by the Department of Health and Human Services (HHS) under the Select Agent Programs of the Centers for Disease Control and Prevention (CDC) and the Animal and Plant Health Inspection Service (APHIS) to carry out studies on highly pathogenic avian influenza. At present, H5N1 Avian Influenza does not pass efficiently in human-to-human transmissions. However, it is feared the virus, whose mortality rate in infected humans exceeds 60%, will evolve to spark global pandemic. Scientific publications attribute high mortality rates to evidence of H5N1 spreading through the bloodstream to organs and other regions of the body not normally affected by influenza viruses.
